HEC Pharm

What HEC Pharm does

HEC Pharm (广东东阳光药业股份有限公司 / Sunshine Lake Pharma Co., Ltd.) is a vertically integrated Chinese pharmaceutical company founded in 2003 and headquartered in Dongguan, China. It operates across drug discovery, manufacturing, and commercialization for innovative drugs, modified new drugs, generics, and biosimilars, with strategic focus on anti-infectives, chronic diseases, and oncology therapeutic areas. Following its August 2025 listing on the Hong Kong Stock Exchange (06887.HK) via merger-absorption of Yichang HEC Changjiang Pharmaceutical, the company employs 6,000+ staff including 1,100+ R&D personnel, holds 2,500+ invention patent applications and 1,300+ granted patents, and has 68 products approved in Europe and the US. Its commercial portfolio includes Kewei® oseltamivir (the leading oseltamivir brand in China and first pediatric formulation globally), Dongweien® emitasvir and the Encofosbuvir/Netanasvir HCV combination, the Yibigan® insulin glargine franchise (BLA under US FDA review), and creflotinib for AML.

The company's clinical pipeline includes HCN30227 (siRNA for chronic hepatitis B using the proprietary HEC-GalNova liver-targeting delivery system), HEC169584 (a THR-β agonist for NASH discovered via the HEC-GEN model), Ifenidone (Phase II data for IPF), and creflotinib (FLT3 inhibitor, Phase III). It operates the State Key Laboratory of Anti-Infective Drug Development (national-level research platform) and three core R&D platforms covering chemical drug discovery, biologics, and innovative formulation technologies.

HEC Pharm has built a proprietary AI infrastructure spanning molecular generation (HEC-GEN), retrosynthesis planning (HEC-SynAI), formulation design (HEC-PharmAI), pharmacokinetics prediction (HEC-PK), and literature/patent intelligence (HEC-Finder), consolidated under an integrated AIDD platform and an AI4S Joint Laboratory with DeepTech. Revenue derives from pharmaceutical product sales via a direct global sales network covering China domestic, Europe, and North America, supplemented by out-licensing of innovative pipeline assets such as HEC88473 to Apollo (UK) and creflotinib commercialization rights to 3SBio.

Name

HEC Pharm

Legal name

广东东阳光药业股份有限公司

Website

https://hecpharm.com

Company type

Public

Founded year

2003

Operating status

Ipo

Headcount range

1,001–5,000 employees

Short description

HEC Pharm (广东东阳光药业股份有限公司) is a vertically integrated Chinese pharmaceutical company founded in 2003, focused on anti-infectives, chronic disease, and oncology therapeutics. Listed on HKEX as 06887.HK in August 2025, the company develops, manufactures, and commercializes innovative drugs, generics, and biosimilars across China, Europe, and North America.

Ownership category

akta.pro rank

Headquarters

HQ city

Dongguan

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue from sales of innovative drugs, modified new drugs, generic drugs, and biosimilars across therapeutic areas including anti-infectives, chronic diseases, and oncology. Products sold globally through own sales network.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

HEC Pharm is a vertically integrated pharmaceutical company engaged in the R&D, manufacturing, and commercialization of innovative drugs, modified new drugs, generic drugs, and biosimilars. The company strategically focuses on anti-infective, chronic disease, and oncology therapeutic areas, leveraging AI-driven drug discovery platforms across the full R&D-to-CMC pipeline. It operates a global sales network covering China, Europe, and North America.

Product overview

HEC Pharm operates as a vertically integrated pharmaceutical company combining independent R&D platforms, international-standard manufacturing, and a global sales network. The portfolio consists of six AI-powered drug discovery platform modules (HEC-SynAI for retrosynthetic planning, HEC-Finder for literature/patent intelligence, HEC-PharmAI for formulation, HEC-PK for pharmacokinetics prediction, HEC-GEN for molecular generation, and the integrated HEC Drug Intelligent Discovery Platform), five commercialized pharmaceutical products (Kewei® oseltamivir phosphate granules and capsules for influenza, Dongweien® emitasvir phosphate capsules for HCV, Yibigan® insulin glargine injection for diabetes, and the 2025-approved艾考磷布韦/磷酸萘坦司韦 HCV combination), and multiple clinical-stage candidates (HECN30227 siRNA for hepatitis B, HEC169584 THR-β agonist for NASH, creflotinib for AML, and ifeonidone for IPF). The company strategically focuses on anti-infective, chronic disease, and oncology therapeutic areas, leveraging AI to accelerate the full drug discovery-to-CMC pipeline.

Differentiator

Problem solved

Functional benefit

Brands

• 可威® (Kewei®): 磷酸奥司他韦颗粒 (Oseltamivir Phosphate Granules) and 磷酸奥司他韦胶囊 (Oseltamivir Phosphate Capsules) — leading oseltamivir brand for influenza treatment and prevention, first pediatric-appropriate oseltamivir formulation globally. Awarded China Patent Gold Award in 2025.
• 东卫恩® (Dongweien®)
• 东卫卓® (Dongweizhuo®)
• 东英贺® (Dongyinghe®)
• 宜必甘® (Yibigan®)
• HEC-SynAI
• HEC-Finder
• HEC-PK (HEC-PK Model 1.0)
• HEC-PharmAI
• HEC-GEN
• HEC-GalNova (N-乙酰半乳糖胺)
• 宜必锐® (Yibirui®)
• 宜必霖®R (Yibilin®R)

Products and services

• Kewei® Oseltamivir Phosphate Granules (可威® 磷酸奥司他韦颗粒) Oseltamivir phosphate granules for treatment and prevention of influenza A and B in adults and children aged 1 year and above. First pediatric-specific anti-influenza formulation globally, with leading market share in China.
• Kewei® Oseltamivir Phosphate Capsules (可威® 磷酸奥司他韦胶囊) Oseltamivir phosphate capsules for treatment of influenza A and B in adults and children aged 1 year and above (within 48 hours of symptom onset) and prevention in adults and adolescents aged 13 years and above.
• Dongweien® Emitasvir Phosphate Capsules (东卫恩® 磷酸依米他韦胶囊) NS5A inhibitor used in combination with sofosbuvir for treatment of genotype 1 non-cirrhotic chronic hepatitis C in adults. Overall SVR12 rate of 99.8%. China's only hepatitis C treatment drug with proprietary independent IP.
• Yibigan® Insulin Glargine Injection (宜必甘® 甘精胰岛素注射液)

Quantifiable outcome

• HECN30227 siRNA drug: achieved 96% FVC decline delay vs 47% for pirfenidone in IPF Phase II trial
• +4 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• 3SBio (三生制药 / 沈阳三生制药有限责任公司)coreChannel Partner/ Reseller/ Distributor · 25 November 2024HEC Pharm granted 3SBio exclusive commercialization rights for Creflotinib (benzenesulfonic acid crenoltinib) in mainland China. HEC Pharm receives RMB 60 million upfront payment plus potential regulatory and commercial milestone payments. HEC Pharm continues to be responsible for R&D, registration (as MAH), and manufacturing while 3SBio handles exclusive commercialization. Agreement effective for at least 15 years from first commercial sale.
• DeepTech (深势科技)coreTechnology or Integration · 28 August 2024HEC Pharm and DeepTech established an AI4S Joint Laboratory focused on high-value R&D scenarios in biomedicine. DeepTech provides its science AI platform including Hermite drug design platform, RiDYMO difficult-to-drug target R&D platform, and scientific model system DeepPot · YuZhi. HEC Pharm integrates these AI tools into its AIDD platform to accelerate target discovery and preclinical candidate screening. Full strategic cooperation agreement signed at 2024 Science Intelligence Forum.
• Apollo (UK)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2024HEC Pharm licensed HEC88473 (innovative drug) for exclusive development and commercialization rights outside Greater China to UK-based Apollo company. Deal value close to USD 1 billion. Represents major out-licensing BD deal for HEC Pharm's innovative pipeline.
• Baidu Health (百度健康)minorGTM or Marketing Partner · 1 January 2024HEC Pharm partnered with Baidu Health on digital marketing including keyword search optimization, content optimization, and professional Q&A for influenza and related disease education. Collaborated on 'Influenza High-Incidence Season Prevention Should Come First' public welfare campaign with CCTV and Baidu Health.

Scale indicators18 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• BeiGene: Chinese-headquartered oncology-focused innovative pharma with HKEX and Nasdaq listings, global commercial footprint, and partnerships with multinational pharma (Amgen, Novartis). Comparable go-global strategy and HKEX listing to HEC, though more concentrated in oncology.
• Hutchmed (HUTCHMED): Hong Kong and Nasdaq-listed Chinese innovative oncology pharma with global out-licensing partnerships (AstraZeneca, Eli Lilly). Comparable to HEC in its pursuit of innovative drug development, HKEX listing, and strategy of combining Chinese R&D with global commercialization partnerships.
• Innovent Biologics: Chinese innovative biologics company with HKEX listing and a portfolio including oncology and chronic disease biologics with multiple NDA-stage assets. Comparable to HEC's biologic and biosimilar strategy and its evolving pipeline of innovative candidates.
• Hansoh Pharmaceutical: Hong Kong-listed Chinese pharma specializing in innovative drugs across oncology, anti-infectives, and CNS, with a rapidly growing R&D pipeline. Similar mid-cap profile to HEC with comparable HK listing and focus on transitioning from generics to innovative therapeutics.
• Jiangsu Hengrui Pharmaceuticals: China's largest innovative pharmaceutical company with a comparable diversified pipeline spanning oncology, anti-infectives, and chronic diseases. Like HEC, Hengrui is vertically integrated with R&D, manufacturing, and global commercialization (FDA-approved products). Both companies target similar therapeutic areas and pursue out-licensing strategies for global expansion.
• CSPC Pharmaceutical Group: Hong Kong-listed Chinese pharma with similar breadth across innovative drugs, generics, and biosimilars, including significant anti-infective and oncology franchises. CSPC's vertical integration from API through commercial sales and its HKEX Main Board listing make it a directly comparable platform business model to HEC.
• Shanghai Fosun Pharmaceutical: Diversified Chinese pharma with vertically integrated operations spanning innovative drugs, generics, biosimilars, and international assets (acquired Gland Pharma). Comparable scale and breadth of therapeutic areas including anti-infectives, and similar HKEX A-share dual listing structure.
• Sino Biopharmaceutical: Major Chinese pharma with a diversified therapeutic portfolio including hepatitis drugs, oncology, and chronic disease products. Through its subsidiary Chia Tai Tianqing, it directly competes in the anti-infective space. Listed on HKEX, providing a directly comparable public-market peer.
• Chia Tai Tianqing (Sino Biopharm subsidiary): Anti-infective and oncology-focused Chinese pharma and direct competitor to HEC's Kewei franchise. Both companies compete in antiviral therapeutics and hepatitis treatments, with similar hospital sales channels and NRDL-driven commercial dynamics.

Others

• WuXi AppTec: Chinese pharmaceutical R&D services platform providing CRO/CDMO capabilities. Not a direct competitor but an adjacent ecosystem participant whose services HEC could potentially use or whose tech stack overlaps with HEC's AI-driven discovery platform investments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hec-group

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HEC Pharm